UTHR Q2 2019 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$374M-16.0% YoY

Gross Profit

$347M92.9% margin

Operating Income

$221M59.3% margin

Net Income

$205M54.9% margin

EPS (Diluted)

$4.66

QoQ Revenue Growth

+3.0%

Cash Flow

Operating Cash Flow

$133M

Free Cash Flow

$113M

Stock-Based Comp.

-$37M

Balance Sheet

Total Assets

$3.9B

Total Liabilities

$1.3B

Stockholders' Equity

$2.6B

Cash & Equivalents

$881M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$374M	$445M	-16.0%
Gross Profit	$347M	$383M	-9.4%
Operating Income	$221M	$217M	+1.8%
Net Income	$205M	$173M	+18.6%

Revenue Segments

Remodulin

$156M42%

Tyvaso

$110M29%

Orenitram

$54M14%

Adcirca

$29M8%

Unituxin

$25M7%

Geographic Segments

U

$340M91%

European Union And Others

$34M9%